证券代码：300009 证券简称：安科生物 安徽安科生物工程（集团）股份有限公司 投资者关系活动记录表 编号：2019-002 | --- | --- | --- | |-----------------------------|--------------------------------------|------------------------------------------------------| | | | | | | | | | 投 资 者 关 系 活 动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 □ 新闻发布会 | □ 业绩说明会 □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参 与 单 位 名 称 及 | | 光大资管 赵**；新华基金 王*；兴全基金 隋*；中泰证券 | | 人员姓名 | 赵 * | | | | | | | 时间 | 2019 年 9 月 12 日 13:30 | | | 地点 | 公司 A 座 1002 会议室 | | | 上 市 公 司 接 待 人 员姓名 | | 董事会 ...

证券代码：300009 证券简称：安科生物 安徽安科生物工程（集团）股份有限公司 投资者关系活动记录表 编号：2018-001 | --- | --- | --- | |--------------|---------------------------------|------------------------------------------------------------| | | | | | 投资者关系活 | □ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | √ 其他 （ 现场交流与网络直播 ） | | | 参与单位名称 | | 参加现场活动：证券时报、中国证券报、西南证券、中信证券、 | | 及人员姓名 | | 方正证券、东吴证券、国泰君安证券、渤海证券、太平洋证券、招 | | | | 商证券、财通证券、华安证券、国信证券、国联证券、万联证券、 | | | | 华金证券、华创证券、中天国证券、国都证券、上海希瓦资产管 | | | | 理有限公司、浙江中大投资集团有 ...

证券代码：300009 证券简称：安科生物 安徽安科生物工程（集团）股份有限公司 投资者关系活动记录表 编号：2018-002 | --- | --- | --- | |-----------------------------|--------------------------------------|---------------------------------------------------------| | | | | | 投 资 者 关 系 活 动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参 与 单 位 名 称 及 | 浙商证券 陈**；投资快报 吴*；沈*；汤 | *；谬* ；谢*；罗 * | | 人员姓名 | | | | | *；李**；周* | ；王*；周*；田 *；麦** | | 时间 | 2018 年 8 月 29 日 | 16:00 | | 地点 | 公司 A 座 902 会议室 | | ...

证券代码：300009 证券简称：安科生物 安徽安科生物工程（集团）股份有限公司 投资者关系活动记录表 编号：2020-003 | --- | --- | --- | |-------------------------------|--------------------------------|-------------------------------------------------------| | | | | | | | | | 投 资 者 关 系 活 动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参 与 单 位 名 称 及 人员姓名 | | 国盛证券 杨**；建信养老金 蒋*；东方证券资管 解*；湘财 | | | 基金 徐 ** | | | 时间 | 2020 年 11 月 9 日 | 15:00 | | 地点 | 公司 A 座 902 会议室 | | | 上 市 公 司 接 待 人 员姓名 | | 董事 ...

1 / 9 证券代码：300009 证券简称：安科生物 安徽安科生物工程（集团）股份有限公司 投资者关系活动记录表 编号：2020-004 | --- | --- | --- | |----------------------|-------------------------------|------------------------------------------------------| | | | | | 投 资 者 关 系 活 动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参 与 单 位 名 称 及 | | 帮您调研 吴**；帮您调研 马**；帮您调研 荆*；帮您调研 | | 人员姓名 | | 吴**；帮您调研 陈*；帮您调研 李*；帮您调研 杨*；帮您 | | | | | | | 调研 王 * ；帮您调研 赵 | ** ；帮您调研 朱*；众奂投资 盛 * | | | * ；珀源私募 韩 ** | ；富升投 ...

Group 1: Company Performance in 2020 - The overall business performance in 2020 was significantly impacted by the pandemic, particularly in Q1, with a notable recovery starting in Q2 as sales of growth hormone began to rise [2][3] - Interferon sales were initially affected but recovered as domestic pandemic conditions improved, leading to a stable overall performance by the end of the year [3] - Subsidiaries experienced varying degrees of impact, with some achieving revenue stability by Q3, while others, like the Chinese medicine subsidiary, faced significant challenges in Q1 [3] Group 2: Future Strategic Direction - The company has begun to adjust its strategic direction since 2020, focusing on core business areas and optimizing resource allocation towards gene-engineered drugs [3][4] - Plans include upgrading existing products, reducing investment in non-core projects, and emphasizing high-quality oncology drugs [3] - The company aims to enhance subsidiary management and employee motivation to create value for shareholders [3] Group 3: Growth Hormone Insights - Growth hormone is recognized for its safety and efficacy, having been used globally for nearly 40 years, with a strong clinical validation [4][5] - The market for growth hormone is expected to grow significantly, with ongoing increases in patient numbers despite pandemic challenges [4] - The company is actively expanding its market share in the powdered injection segment while also developing long-acting growth hormone formulations [4][5] Group 4: Market Barriers and Competition - Brand recognition is a significant barrier in the growth hormone market, with the company’s product gaining trust and reputation among patients [5] - The company is addressing the declining birth rates by promoting awareness and education about growth hormone among healthcare providers and parents [5] - The gross margin for interferon and growth hormone is approximately 90%, with interferon having a slightly lower margin [5] Group 5: R&D Progress - The company is advancing its research on various monoclonal antibodies and long-acting growth hormone, with several products in different stages of clinical trials [5] - New production capacity for 20 million units has been submitted for approval, which will enhance market promotion efforts once approved [4][5]

Group 1: Production and Sales Progress - The annual production capacity of the recombinant human growth hormone production line is 20 million units, with the expansion project completed last year and currently undergoing verification with the National Medical Products Administration [2] - The sales volume of recombinant human growth hormone injection exceeded the total sales of the previous year in Q1 2021, indicating a positive market outlook [3] - The company is planning to build new production lines for recombinant human growth hormone to meet market demand [2] Group 2: Regulatory and Approval Status - The application for new specifications of recombinant human growth hormone injection is currently in the sample inspection phase, with expected approval around mid-year [3] - The HER-2 monoclonal antibody clinical trial is being conducted according to the national biosimilar standards, aiming for production approval as the second HER-2 biosimilar in China [4] Group 3: Strategic Development and Marketing - The company has adjusted its strategic direction since 2020, focusing on gene-engineered drugs and enhancing brand influence to increase market share [3] - The marketing strategy will combine online and offline promotion, with an expected increase in sales expenses compared to 2020 due to more offline activities [4] Group 4: Research and Development Initiatives - The company is actively involved in the development of CAR-T cell therapy, with ongoing clinical research and preparations for regulatory submissions in both China and the U.S. [4] - The company is also preparing to launch a new injection device for growth hormone that alleviates injection fears and enhances user convenience [5]

证券代码：300009 证券简称：安科生物 编号：2021-005 | --- | --- | --- | |-------------------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：300009 证券简称：安科生物 安徽安科生物工程（集团）股份有限公司 投资者关系活动记录表 编号：2021-006 | --- | --- | --- | |-----------------------|--------------------------------------------------------|------------------------------------------------------------------------------| | | | | | 投资者关系活动 | √特定对象调研 □分析师会议 | | | 类别 | □媒体采访 □业绩说明会 | | | | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称及 | 国金证券 赵 ** ；月湖资本史 | ** ；海羽投资 蔡 ** ；均怡地产 | | 人员姓名 | 易**；大湾汇 徐**；大湾汇 ** ；大湾汇 高**；大湾汇 | 崔*；大湾汇 王*；大湾汇朱 李* | | 时间 | 2021 年 7 月 14 日 10: ...

证券代码：300009 证券简称：安科生物 安徽安科生物工程（集团）股份有限公司 投资者关系活动记录表 编号：2022-009 | --- | --- | --- | |-------------------------|-----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...